Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
View Patent ↗Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC 50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.
1. A method of treating cancer, comprising:
(a) treating a patient with a therapeutically effective amount of a halo-ester isoborneol compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof, wherein said halo-ester isoborneol compound at least partially inhibits the activity of Replication Protein A in vivo, wherein the cancer is non-small cell lung cancer or ovarian cancer.
2. The method according to claim 1 , further comprising the step of:
(b) treating the patient with a therapeutically effective amount of at least one compound that damages DNA in vivo.
3. The method according to claim 2 , wherein the compound that damages DNA in vivo promotes the formation of intra strand linkages between adjacent nucleotides.
4. The method according to claim 3 , wherein the compound that damages DNA is cisplatin, or a pharmaceutically acceptable salt thereof.
5. The method according to claim 2 , wherein the step of treating the patient with the compound that damages DNA occurs before the step of treating the patient with the halo-ester isoborneol compound.
6. The method according to claim 1 , wherein the therapeutically effective amount is between about 100 mg/kg of patient body weight and about 300 mg/kg of patient body weight.
7. The method according to claim 6 , wherein the therapeutically effective amount is about 200 mg/kg of patient body weight.
8. The method according to claim 1 , wherein said therapeutically effective amount is less than about 400 mg of pharmaceutically active compound per kg of patient body weight.
9. The method according to claim 8 , wherein said therapeutically effective amount is between about 50 mg to about 10 mg of pharmaceutically active compound per kg of patient body weight.